首页> 外文OA文献 >A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

【2h】

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

机译：与2型糖尿病患者的安慰剂和开放标签Liraglutide相比，新型一次每周人GLP-1模拟，半血糖蛋白酶的2阶段，随机剂量寻找研究与2型糖尿病患者相比

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Michael A. Nauck; John R. Petrie; Giorgio Sesti; Edoardo Mannucci; Jean-Pierre Courrèges; Marie L. Lindegaard; Christine B. Jensen; Stephen L. Atkin;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes [J] . Nauck Michael A., Petrie John R., Sesti Giorgio, Diabetes care . 2016,第2期

机译：与2型糖尿病患者进行的每周一次的新型人类GLP-1类似物Semaglutide与安慰剂和开放标签利拉鲁肽比较的第2期随机研究
2. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes a randomized, open-label trial [J] . PratleyR.E., NauckM.A., BaileyT., Diabetes care . 2012,第10期

机译：在二甲双胍治疗的2型糖尿病患者中，在52周后从DPP-4抑制剂西他列汀转换为人GLP-1类似物利拉鲁肽的疗效和安全性是一项随机，开放标签试验
3. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study [J] . Miyagawa J., Odawara M., Takamura T., Diabetes, obesity & metabolism . 2015,第10期

机译：在日本2型糖尿病患者中，每周一次的胰高血糖素样肽1受体激动剂dulaglutide不逊于每天一次的liraglutide，并且优于安慰剂：一项为期26周的随机III期研究
4. A series of open-label studies comparing various formulations of orally administeredinsulin (Oralin) in patients with Type -1 Diabetes Mellitus (DM) [C] . Jaime Guevara-Aguirre, Marco Guevara, Jeannette Saavedra Annual meeting exposition of the Controlled Release Society . 2005

机译：一系列开放标签研究比较了-1型糖尿病（DM）患者口服胰岛素（Oralin）的各种配方
5. A randomized, open-label, intervention study to evaluate the effect of diet composition on weight gain in obese, type 2 diabetes patients receiving intensive insulin therapy. [D] . Villareal, Roland. 2008

机译：一项随机，开放标签，干预性研究，以评估饮食结构对接受强化胰岛素治疗的肥胖2型糖尿病患者体重增加的影响。
6. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter Prospective Randomized Open-Label Blinded-Endpoint Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study) [O] . Hiroshi Nomoto, Chiho Oba-Yamamoto, Yuka Takahashi, 2021

机译：从紫胶蛋白质或杜拉格兰蛋白转换为皮下半蛋白质对2型糖尿病患者的葡萄糖代谢和治疗满意度的影响：多中心前瞻性随机开放标签盲终点并联集团比较研究的议定书（Switch-Sema） 1研究）
7. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes a randomized, open-label trial [O] . R.E. Pratley, M.A. Nauck, T. Bailey, 2012

机译：在二甲双胍治疗的2型糖尿病患者中，在52周后从DPP-4抑制剂西他列汀转换为人GLP-1类似物利拉鲁肽的疗效和安全性是一项随机，开放标签试验

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

著录项

引文网络

相似文献

相关主题

期刊订阅